Chercheur

    Nathalie Alos , M.D.

    nathalie.alos@recherche-ste-justine.qc.ca
    Nathalie Alos
    Axe de recherche
    Maladies musculosquelettiques et réadaptation
    Thème de recherche
    Étude des déformations du rachis et des pathologies musculosquelettiques
    Adresse
    CHUSJ - Centre de Recherche

    Téléphone
    514 345-4931 #2993

    Fax
    514 345-4988

    Intérêts de recherche

    Ses intérêts de recherche portent actuellement sur l'ostéoporose secondaire en pédiatrie. Son intérêt premier pour les complications endocriniennes et métaboliques à long terme des traitements anticancéreux des enfants suivis en hémato-oncologie pédiatrique reste une de ses priorités de recherche.

    Sommaire de carrière

    Pédiatre de formation, Dr Nathalie Alos a obtenu ses diplômes (MD et spécialité en pédiatrie) en 1991 au sein des Universités de Médecine de Toulouse et Bordeaux, en France. Suite à une formation complémentaire de trois ans en hémato-oncologie pédiatrique, elle se spécialisa en endocrinologie pédiatrique en s'intéressant tout particulièrement aux complications endocriniennes des traitements des cancers des enfants. Une bourse de recherche du Centre de recherche du CHU Sainte-Justine lui permit de rejoindre l'équipe d'endocrinologie pédiatrique de l'établissement, affilié à l'Université de Montréal, pour deux années de recherche clinique en endocrinologie pédiatrique. Après avoir occupé pendant deux ans le poste de chef de service de pédiatrie de l'Hôpital de Narbonne (France), elle obtint une bourse de recherche de la Société Européenne d'Endocrinologie Pédiatrique (ESPE) afin de réaliser un projet de deux ans de recherche dans le domaine des maladies osseuses de l'enfant dans l'Unité du docteur Francis Glorieux à l'Hôpital Shriners pour enfants de Montréal (Université McGill). Depuis début mars 2001, Dr Alos fait partie de l'équipe d'endocrinologie pédiatrique et du métabolisme du CHU Sainte-Justine en tant que professeur adjoint du Département de pédiatrie de l'Université de Montréal avec un domaine d'expertise dans les maladies métaboliques osseuses et désordres du métabolisme phosphocalcique impliquant les systèmes de régulation endocriniens et des cytokines dans les pathologies pédiatriques.

Publications

Skeletal findings in the first 12 months following initiation of glucocorticoid therapy for pediatric nephrotic syndrome - Phan V, Blydt-Hansen TD, Feber J, Alos N, Arora S, Atkinson S, Bell L, Clarson C, Couch R, Cummings E, Filler G, Grant R, Grimmer J, Hébert D, Lentle B, Ma J, Matzinger M, Midgley J, Pinsk M, Rodd C, Shenouda N, Stein R, Stephure D, Taback S, Williams K, Rauch F, Siminoski K, Ward LM, Canadian STOPP Consortium. Skeletal findings in the first 12 months following initiation of glucocorticoid therapy for pediatric nephrotic syndrome
. Osteoporosis Int 2014; 25(2): 627-637.

Rising serum thyroxine levels and chorea in graves' disease - Leblicq C, Duval M, Carmant L, Van Vliet G, Alos N. Rising serum thyroxine levels and chorea in graves' disease. Pediatrics 2013; 131(2): e616-619.

Effectiveness of pamidronate as treatment of symptomatic osteonecrosis occurring in children treated for acute lymphoblastic leukemia - Leblicq C, Laverdière C, Décarie JC, Delisle JF, Isler M, Moghrabi A, Chabot G, Alos N. Effectiveness of pamidronate as treatment of symptomatic osteonecrosis occurring in children treated for acute lymphoblastic leukemia. Pediatr Blood Cancer 2013; 60(5): 741-747.

The development of bone mineral lateralization in the arms - Siminoski K, Lee KC, Abish S, Alos N, Bell L, Blydt-Hansen TD, Couch R, Cummings E, Ellsworth J, Feber J, Fernandez C, Halton J, Huber AM, Israels S, Jurencak R, Lang B, Laverdière C, LeBlanc C, Lewis V, Midgley J, Miettunen P, Oen K, Phan V, Pinsk M, Rauch F, Rodd C, Roth J, Saint-Cyr C, Scuccimarri R, Stephure D, Taback S, Wilson B, Ward LM, the Canadian STOPP Consortium (National Pediatric Bone Health Working Group). The development of bone mineral lateralization in the arms. Osteoporosis Int 2013; 24(3): 999-1006.

Association between lean and fat mass and indicators of bone health in prepubertal Caucasian children - Kâ K, Rousseau MC, Lambert M, O'Loughlin J, Henderson M, Tremblay A, Alos N, Nicolau B. Association between lean and fat mass and indicators of bone health in prepubertal Caucasian children. Horm Res Ped 2013; 80(3): 154-162.

Glucocorticoid-related changes in body mass index among children and adolescents with rheumatic diseases - Shiff N, Brant R, Guzman J, Cabral DA, Huber AM, Miettunen P, Roth J, Scuccimarri R, Alos N, Atkinson S, Collet JP, Couch R, Cummings E, Dent P, Ellsworth J, Hay J, Houghton K, Jurencak R, Lang B, Larché M, LeBlanc C, Rodd C, Saint-Cyr C, Stein R, Stephure D, Taback S, Rauch F, Ward LM, Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) Consortium. Glucocorticoid-related changes in body mass index among children and adolescents with rheumatic diseases. Arthritis Care Res (Hoboken) 2013; 65(1): 113-121.

A search for variables predicting cortisol response to low-dose corticotropin stimulation following supraphysiological doses of glucocorticoids - Wildi-Runge S, Deladoëy J, Bélanger C, Deal C, Van Vliet G, Alos N, Huot C. A search for variables predicting cortisol response to low-dose corticotropin stimulation following supraphysiological doses of glucocorticoids. J Pediatr 2013; 163(2): 484-488.e1.

High incidence of vertebral fractures in children with acute lymphoblastic leukemia 12 months after the initiation of therapy - Alos N, Grant R, Ramsay T, Halton J, Cummings E, Miettunen P, Abish S, Atkinson S, Barr R, Cabral DA, Cairney E, Couch R, Dix D, Fernandes CV, Hay J, Israels S, Laverdière C, Lentle B, Lewis V, Matzinger M, Rodd C, Shenouda N, Stein R, Stephure D, Taback S, Wilson B, Williams K, Rauch F, Siminoski K, Ward LM. High incidence of vertebral fractures in children with acute lymphoblastic leukemia 12 months after the initiation of therapy. J Clin Oncol 2012; 30(22): 2760-2767.

Muscle-bone characteristics in children with Prader-Willi syndrome - Edouard T, Deal C, Van Vliet G, Gaulin N, Moreau A, Rauch F, Alos N. Muscle-bone characteristics in children with Prader-Willi syndrome. J Clin Endocrinol Metab 2012; 97(2): E275-281.

Anatomical distribution of vertebral fractures: comparison of pediatric and adult spines - Siminoski K, Lee KC, Jen H, Warshawski R, Matzinger M, Shenouda N, Charron M, Coblentz C, Dubois J, Kloiber R, Nadel H, O'Brien K, Reed M, Sparrow K, Webber C, Lentle B, Ward LM, Laverdière C, Alos N, STOPP Consortium. Anatomical distribution of vertebral fractures: comparison of pediatric and adult spines. Osteoporosis Int 2012; 23(7): 1999-2008.

Skeletal findings in children recently initiating glucocorticoids for the treatment of nephrotic syndrome - Feber J, Gaboury I, Ni A, Alos N, Arora S, Bell L, Blydt-Hansen TD, Clarson C, Filler G, Hay J, Hébert D, Lentle B, Matzinger M, Midgley J, Moher D, Pinsk M, Rauch F, Rodd C, Shenouda N, Siminoski K, Ward LM, Laverdière C, Canadian STOPP Consortium. Skeletal findings in children recently initiating glucocorticoids for the treatment of nephrotic syndrome. Osteoporosis Int 2012; 23(2): 751-760.

Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: a national observational study - Rodd C, Lang B, Ramsay T, Alos N, Huber AM, Cabral DA, Scuccimarri R, Miettunen P, Roth J, Atkinson S, Couch R, Cummings E, Dent P, Ellsworth J, Hay J, Houghton K, Jurencak R, Larché M, LeBlanc C, Oen K, Saint-Cyr C, Stein R, Stephure DK, Taback S, Lentle B, Matzinger M, Shenouda N, Moher D, Rauch F, Siminoski K, Ward LM, Laverdière C, Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) Consortium. Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: a national observational study. Arthritis Care Res (Hoboken) 2012; 64(1): 122-131.

Efficacy and safety of 2-year etidronate treatment in a child with generalized arterial calcification of infancy - Edouard T, Chabot G, Miró J, Buhas D, Nitschke P, Lapierre C, Rutsch F, Alos N. Efficacy and safety of 2-year etidronate treatment in a child with generalized arterial calcification of infancy. Eur J Pediatr 2011; 170(12): 1585-1590.

Short- and long-term outcome of patients with pseudo-vitamin D deficiency rickets treated with Calcitriol - Edouard T, Alos N, Chabot G, Roughley P, Glorieux FH, Rauch F. Short- and long-term outcome of patients with pseudo-vitamin D deficiency rickets treated with Calcitriol. J Clin Endocrinol Metab 2011; 96(1): 82-89.

Is ultrasonography useful in predicting thyroid cancer in children with thyroid nodules and apparently benign cytopathologic features? - Saavedra J, Deladoëy J, Saint-Vil D, Boivin Y, Alos N, Deal C, Van Vliet G, Huot C. Is ultrasonography useful in predicting thyroid cancer in children with thyroid nodules and apparently benign cytopathologic features?. Horm Res Ped 2011; 75(4): 269-275.

Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders - Huber AM, Gaboury I, Cabral DA, Lang B, Ni A, Stephure DK, Taback S, Dent P, Ellsworth J, LeBlanc C, Saint-Cyr C, Scuccimarri R, Hay J, Lentle B, Matzinger M, Shenouda N, Moher D, Rauch F, Siminoski K, Ward LM, Alos N, Laverdière C, Phan V, Dubois J, Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) Consortium. Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders. Arthritis Care Res (Hoboken) 2010; 62(4): 516-526.

Non-immune goiter and hypothyroidism in a 19-week fetus: a plea for conservative treatment - Stoppa-Vaucher S, Francoeur D, Grignon A, Alos N, Polhenz J, Hermanns P, Van Vliet G, Deladoëy J. Non-immune goiter and hypothyroidism in a 19-week fetus: a plea for conservative treatment. J Pediatr 2010; 156(6): 1026-1029.

Comparison of adolescents with Klinefelter syndrome according to the circumstances of diagnosis: amniocentesis vs clinical signs - Girardin C, Lemyre E, Alos N, Deal C, Huot C, Van Vliet G. Comparison of adolescents with Klinefelter syndrome according to the circumstances of diagnosis: amniocentesis vs clinical signs. Horm Res 2009; 72(2): 98-105.

[Bone mass acquisition in children: pathophysiology and evaluation] - Alos N, Rauch F. [Bone mass acquisition in children: pathophysiology and evaluation]. Arch Pediatr 2009; 16(6): 591-593.

Advanced vertebral fracture among newly diagnosed children with acute lymphoblastic leukemia: results of the Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) research program - Halton J, Gaboury I, Grant R, Alos N, Cummings E, Matzinger M, Shenouda N, Lentle B, Abish S, Atkinson S, Cairney E, Dix D, Israels S, Stephure DK, Wilson B, Hay J, Moher D, Rauch F, Siminoski K, Ward L, Laverdière C, Phan V, Dubois J, Canadian STOPP Consortium. Advanced vertebral fracture among newly diagnosed children with acute lymphoblastic leukemia: results of the Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) research program. J Bone Miner Res 2009; 24(7): 1326-1334.

Enzyme replacement therapy in pediatric patients with Gaucher disease: what should we use as maintenance dosage? - Brunel-Guitton C, Rivard G-É, Galipeau J, Alos N, Miron MC, Therrien R, Mitchell GA, Lapierre J-G, Lambert MA. Enzyme replacement therapy in pediatric patients with Gaucher disease: what should we use as maintenance dosage?. Mol Genet Metab 2009; 96(2): 73-76.

Do estrogens impact adolescent idiopathic scoliosis? - Leboeuf D, Letellier K, Alos N, Moldovan F. Do estrogens impact adolescent idiopathic scoliosis? Trends Endocrinol Metab 2009; 20(4): 147-152.

FGF8 is a key ligand for FGFR1 in GnRH ontogeny: lessons from human and mice - Falardeau J, Chung WC, Beenken A, Plummer L, Sidis I, Raivio T, Dwyer A, Quinton R, Na S, Hall J, Huot C, Alos N, Cole L, Hughes VA, Mohammadi M, Tsai P, Pitteloud N. FGF8 is a key ligand for FGFR1 in GnRH ontogeny: lessons from human and mice. J Clin Invest 2009; (sous presse).

The International Research Society of Spinal Deformities (IRSSD) and its contribution to science - Bagnall K, Grivas TB, Alos N, Asher M, Aubin C-É, Burwell RG, Dangerfield PH, Edouard T, Hill D, Lou E, Moreau A, O'Brien J, Stokes I, Weiss HR, Raso J. The International Research Society of Spinal Deformities (IRSSD) and its contribution to science. Scoliosis 2009; 4(1): 28 (on line).

Preemptive high-dose fluticasone for viral-induced asthma in preschool-aged children: a randomized controlled trial - Ducharme F, Lemire C, Noya F, Davis G, Alos N, Leblond H, Savdie C, Dollet JP, Rivard G, Platt RW. Preemptive high-dose fluticasone for viral-induced asthma in preschool-aged children: a randomized controlled trial. N Engl J Med 2009; 360(4): 339-353.

Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice - Falardeau J, Chung WC, Beenken A, Raivio T, Plummer L, Sidis Y, Jacobson-Dickman EE, Eliseenkova AV, Ma J, Dwyer A, Quinton R, Na S, Hall J, Huot C, Alos N, Pearce S, Cole L, Hughes V, Mohammadi M, Tsai P, Pitteloud N. Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. J Clin Invest 2008; 118(8): 2822-2831.

Mutations in prokineticin 2 (PROK2) and PROK2 receptor (PROKR2) in human gonadotrophin-releasing hormone deficiency: molecular genetics and clinical spectrum - Cole L, Sidis Y, Zhang C, Quinton R, Plummer L, Pignatelli D, Hughes VA, Dwyer A, Raivio T, Hayes FJ, Seminara S, Huot C, Alos N, Speiser P, Takeshita A, Van Vliet G, Pearce S, Crowley W, Zhou Q-Y, Pitteloud N. Mutations in prokineticin 2 (PROK2) and PROK2 receptor (PROKR2) in human gonadotrophin-releasing hormone deficiency: molecular genetics and clinical spectrum. J Clin Endocrinol Metab 2008; 93(9): 3551-3559.

Impact of patient characteristics and clinical factors on the decision to initiate growth hormone treatment in Turner syndrome - Khatchadourian K, Huot C, Alos N, Van Vliet G, Deal C. Impact of patient characteristics and clinical factors on the decision to initiate growth hormone treatment in Turner syndrome. Horm Res 2008; 70(5): 300-308.

Cumulative doses of adjunct 131I treatment depend on location of residual thyroid tissue after total thyroidectomy in differentiated thyroid cancer - Saint-Vil D, Emran MA, Lambert R, Alos N, Turpin S, Huot C. Cumulative doses of adjunct 131I treatment depend on location of residual thyroid tissue after total thyroidectomy in differentiated thyroid cancer. J Pediatr Surg 2007; 42(5): 853-856.

Pamidronate: treatment for severe Hypercalcemia in neonatal subcutaneous fat necrosis - Alos N, Eugène D, Filion M, Powell J, Kokta V, Chabot G. Pamidronate: treatment for severe Hypercalcemia in neonatal subcutaneous fat necrosis. Horm Res 2006; 65(6): 289-294.

L'ostéoporose chez l'enfant, encore méconnue - Lavoie A, Alos N. L'ostéoporose chez l'enfant, encore méconnue. Pharmactuel 2006; 39(1): 22-31.

Downregulation of osteoblast Phex expression by PTH - Alos N, Ecarot B. Downregulation of osteoblast Phex expression by PTH. Bone 2005; 37(4): 589-598.

Le diabète chez l'enfant et l'adolescent - Geoffroy L, Gonthier M, Alos N, et l'équipe de la Clinique du diabète, e. Le diabète chez l'enfant et l'adolescent. Éditions de l'hôpital Sainte-Justine, 2003; 350 pages.

A novel A10E homozygous mutation in the HSD3B2 gene causing severe salt-wasting 3b-hydroxysteroid dehydrogenase deficiency in 46 XX and 46 XY French Canadians - Alos N, Moisan AM, Ward L, Desrochers M, Legault L, Leboeuf G, Van Vliet G, Simard J. A novel A10E homozygous mutation in the HSD3B2 gene causing severe salt-wasting 3b-hydroxysteroid dehydrogenase deficiency in 46 XX and 46 XY French Canadians. J Clin Endocrinol Metab 2000; 85: 1968-1974.

À propos de cette page

Créée le 22 juillet 2014
Signaler ou faire une remarque

Chaque dollar compte !

Merci de votre générosité.

Ce sont les donateurs comme vous qui nous permettent d’accélérer la recherche, de guérir, à chaque année, plus d’enfants et continuer d’offrir un des meilleurs niveaux de santé au monde.

Il est également possible de donner par la poste ou de donner par téléphone au numéro sans frais

1-888-235-DONS (3667)

Nous contacter

514 345-4931

Légal

© 2006-2014 Centre de recherche du CHU Sainte-Justine.
Tous droits réservés.
Avis légaux  Confidentialité  Sécurité

Avertissement

Les informations contenues dans le site « CHU Sainte-Justine » ne doivent pas être utilisées comme un substitut aux conseils d’un médecin dûment qualifié et autorisé ou d’un autre professionnel de la santé. Les informations fournies ici le sont à des fins exclusivement éducatives et informatives.

Consultez votre médecin si vous croyez être malade ou composez le 911 pour toute urgence médicale.

CHU Sainte-Justine